Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30341672 | 1.00 | TDP1 (0.65) | TDP1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16546002 | 0.98 | TDP1 (0.63) | TDP1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16408483 | 0.98 | TDP1 (0.63) | TDP1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10329801 | 0.97 | TDP1 (0.65) | TDP1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20160906 | 0.87 | TDP1 (0.66) | TDP1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL7877444 | 0.85 | SMN1; SMN2 (0.70) | TDP1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12286062 | 0.85 | TDP1 (0.60) | TDP1HPGDSMN1; SMN2PDE10AL3MBTL1 | |
| SCHEMBL15759182 | 0.84 | L3MBTL3 (0.72) | TDP1ALDH1A1L3MBTL1L3MBTL3 | |
| SCHEMBL20254519 | 0.83 | TDP1 (0.61) | TDP1SMN1; SMN2PDE10A | |
| SCHEMBL15633356 | 0.81 | L3MBTL1 (0.52) | TDP1HPGDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018075858-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | SAMUMED, LLC (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | TDP1 641/4885HPGD 2172/4885NPC1 1268/4885 |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | TDP1 2437/4885HPGD 1459/4885NPC1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.